Related by context. All words. (Click for frequent words.) 64 Spiro Rombotis President 63 Georges Gemayel 62 Ron Bentsur 61 Marc Cluzel 60 Per Olof Wallström 60 Harry Palmin President 60 Polymeropoulos 60 CURE AF 59 Phase Ib study 59 Mark A. Sirgo 59 Joshua Boger Ph.D. 59 OvaRex R 59 Dino Dina 59 Rosen ViroPharma 59 Jean Pierre Sommadossi Ph.D. 59 Iris Loew Friedrich 59 phase IIa clinical 58 TEMSO 58 Hans Joachim Lohrisch 58 Corlux 58 ADVANCE PD 58 Frank Verwiel MD 58 phase IIb clinical 58 Caroline Loewy 58 Philip Mease 58 Lars Ekman 57 phase IIb trial 57 Gregory A. Demopulos 57 PFO migraine 57 Jacob Inbar 57 SUCCEED trial 57 Zenvia ™ 57 Roger Perlmutter Amgen 57 Mark HN Corrigan 57 Yves Rosconi President 57 acute mania 57 Chang Ahn Rexahn 57 CRMD# 57 Jean Pierre Lehner 57 Timothy Botello 57 initiate Phase IIb 56 Michael H. Tardugno 56 Lu AA# 56 QTinno TM 56 PRECISE Trial 56 Neil K. Warma 56 Nicole Onetto MD 56 CRD5 56 Phase Ib II 56 David Aviezer 56 pivotal bioequivalence 56 nalbuphine ER 55 BRIM3 55 Phase #b/#a clinical 55 TIMI Study Group 55 oral methylnaltrexone 55 Mace Rothenberg 55 Ben Lipps 55 phase IIa 55 opioid bowel dysfunction 55 SUTENT ® 55 initiate Phase 2b 55 Burt Adelman 55 Camvia 55 Haim Aviv 55 ALSYMPCA 55 Phase Ib IIa 55 Edward Lanphier Sangamo 55 R#/MEM # 55 Alexei Marko 55 Phase III ADT 55 ARISE Phase III 55 alvespimycin 55 Ulrich Dauer CEO 55 initiated Phase Ib 55 EMPOWER ™ 55 rindopepimut 55 IMA# 55 PRIMO CABG 55 multicenter Phase II 55 Phase 1b trial 54 Dr. Arndt Schottelius 54 Klaus Schollmeier 54 NASDAQ TGEN 54 phase Ib 54 Hem Pandya 54 J. Mazzo Ph.D. 54 ONCONASE R 54 Christoph Westphal MD Ph.D. 54 rALLy clinical trial 54 Genz # 54 Oglemilast 54 IIa trial 54 Phase 2b study 54 Sudhir Agrawal D.Phil 54 solanezumab 54 LCP AtorFen 54 Phase 1a clinical 54 leading oral taxane 54 Plicera 54 Orville G. Kolterman 54 Dr. Ayalew Tefferi 54 Candace Kendle PharmD 54 Relovair 54 JP-#/fipamezole 54 Lupuzor 54 Daniel Tasse 54 ABSORB trial 54 BLA filing 54 Phase 2a clinical 54 NP2 Enkephalin 54 Elkan Gamzu Ph.D. 54 ADAGIO study 54 deforolimus 54 Fx #A 54 Elocalcitol 54 T. Flavin 53 Jal Jassawalla 53 Pegloticase 53 Jeffrey H. Buchalter 53 HCD# [002] 53 Phase #/#a 53 TELINTRA R 53 budesonide foam 53 fidaxomicin Phase 3 53 Surfaxin LS 53 Trevor Mundel 53 Phase IIb trials 53 ACCEDE 53 Alzhemed TM 53 Phase 2a trial 53 orally inhaled migraine 53 J. Donald deBethizy 53 GSK# [002] 53 Joseph Loscalzo 53 cannabinor 53 confirmatory clinical 53 budesonide MMX Phase III 53 IND submission 53 ThGRF 53 lorvotuzumab mertansine 53 tramiprosate Alzhemed TM 53 Vojo Vukovic MD Ph.D. 53 Nancy Lurker 53 Aryx 53 Phase 2b clinical 53 Dr. Gussak 53 APEX PD 53 CLIRS 53 PSMA ADC 53 Allovectin 7 53 transmucosal delivery system 53 AA Amyloidosis 53 Michael Narachi 53 Phase III Pivotal 53 including eniluracil ADH 53 Phase 2b trial 52 Phase 2b kidney transplant 52 Venkat Jasti 52 Phase Ib clinical 52 IMPACT IMmunotherapy 52 budiodarone 52 SNT MC# 52 Mr. Mordock 52 Dr. Relkin 52 optimal dosing regimens 52 Elisabeth Lindner CEO 52 phase III ACCLAIM 52 initiate Phase 1b 52 TBC# 52 Peter A. Lankau 52 confirmatory Phase III 52 MEND CABG 52 Phase #b/#a 52 Exherin TM 52 Mr. Rosconi 52 bardoxolone 52 ENRICH trial 52 Phase IIb III 52 MIST II 52 metastatic renal cell 52 REG2 52 ACCLAIM II 52 phase IIb 52 Domorski 52 Emer Leahy 52 Bayer HealthCare Onyx Pharmaceuticals 52 Ocrelizumab 52 Ele Ferrannini 52 initiate multicenter 52 Michael Laphen 52 Jean Claude Tardif 52 Anders Sundstrom 52 Dr. Eugene Braunwald 52 Mipomersen 52 mg/m2 cohort 52 opioid induced bowel dysfunction 52 Bruce Kuhlik 52 TMS Therapy 52 Yatscoff 52 EndoTAG TM -1 52 Gentamicin Surgical Implant 52 MEND CABG II 52 subcutaneous PRO 52 recurrent herpes labialis 52 David Crockford RegeneRx 52 recombinant PSMA vaccine 51 phase Ib clinical 51 Phase IIb clinical trials 51 NASDAQ SLXP today 51 Pier Paolo Pandolfi 51 Phase III confirmatory 51 overactive bladder AA# 51 Hoyoung Huh MD Ph.D. 51 Riccardo Trecroce 51 REVIVE TA 51 Eric Van Cutsem 51 Lofexidine 51 rEV# 51 Hedgehog antagonist 51 Willi Food commented 51 generation URAT1 inhibitor 51 unblinding 51 Daniel Hamburger DeVry 51 Ofer Segev executive 51 Eran Broshy 51 phase 2a 51 unblind 51 Aggrastat ® tirofiban hydrochloride 51 IMPACT DCM 51 constipation predominant irritable bowel 51 post operative ileus 51 Nicholas Borys 51 tolevamer 51 Phase IIIb clinical 51 Phase IIa trial 51 Fodosine 51 Phase IIa clinical 51 Christos Mantzoros 51 OncoGel 51 AGILECT R 51 Mohammad Azab MD 51 confirmatory Phase 3 51 Sentiments soured 51 Phase 2a 51 Society CTOS 51 multicenter Phase 51 phase IIb study 51 PU H# 51 AEG# 51 BrachySil TM 51 poststroke depression 51 3 registrational trial 51 Elisabeth Lindner 51 Chain Intellect 51 CUSTOM III 50 Zemplar Capsules 50 Zeuzem 50 Rik J Deitsch 50 Prodarsan R 50 Kemal Malik 50 multicenter randomized Phase 50 GetGoal Phase III 50 Martin Nicklasson CEO 50 Robert Spanheimer 50 randomized Phase IIb 50 ospemifene 50 Richard Schilsky 50 Bioral Amphotericin B 50 riociguat 50 Torbjorn Bjerke 50 Phase IIB 50 David Sidransky 50 PRESEPT 50 serine protease inhibitor CU# 50 Second Pivotal Phase 50 IIa clinical trial 50 Bruce Cozadd 50 Asher Chanan Khan 50 SNT-MC#/idebenone 50 William Sandborn MD 50 Robert Darretta 50 CHARM Added 50 Alex Lidow 50 Phase III pivotal 50 Dr. Norman Relkin 50 IMiDs R 50 Roman Hovorka 50 CLIRS trial 50 RE LY trial 50 acyclovir Lauriad R 50 C. Warren Olanow 50 midstage trials 50 StemEx R 50 GALNS 50 randomized Phase 2b 50 impedance cardiography ICG 50 Dose escalation 50 assessing T DM1 50 tremelimumab 50 thetreatment 50 Amy Abernethy 50 Phase lll 50 EMPOWER Study 50 elacytarabine 50 macitentan 50 Dr. Pingpank 50 AeroLEF TM 50 Cand5 50 rPA anthrax vaccine 50 Kevin Sharer Amgen 50 Thomas Südhof 50 Steve Cartt Executive 50 BST CarGel R 50 Brian JG Pereira 50 CTEPH 50 TACI Ig 50 Auxilium anticipates 50 RSD# oral 50 Luc Tanguay 49 PANVAC VF 49 Thomas Thuresson 49 tezampanel NGX# 49 Thorough QT 49 Ken Fujioka 49 metastatic sarcomas 49 bavituximab monotherapy trial 49 Yos Shiran 49 VITAL Trial 49 gaboxadol 49 Aram V. Chobanian 49 Phase IIb clinical 49 Rhucin R 49 Gabriel Zada neurosurgeon 49 ACTEMRA TM 49 sNDA submission 49 DSMB recommended 49 ABSORB clinical 49 Phase 1b clinical trials 49 Eugene Flamm 49 Phase #/#a clinical 49 TNF blocker therapy 49 Evoltra TM 49 TNF antagonist 49 MAA submission 49 Randy Tofteland SoftBrands 49 Alfred I. Neugut 49 denileukin diftitox 49 Variani Deputy Interior 49 Phase Ib 49 Phase III registrational 49 Stimuvax R 49 LUX Lung 49 Werner Hacke 49 NADiA ProsVue 49 Gary Ghiselli 49 J. Tyler Haahr 49 Michele Volpi 49 Colin Baigent 49 ofatumumab HuMax CD# 49 gastrointestinal mucositis 49 Breaking Clinical Trials 49 Jean Paul Clozel 49 brentuximab vedotin SGN 49 generation HCV protease 49 rotary VAD 49 intravenous methylnaltrexone 49 Neurodegenerative 49 Dr. Agarwala 49 ZYBRESTAT fosbretabulin 49 subcutaneous methylnaltrexone 49 Phase III clinical 49 JunJing III 49 Dr. Feczko 49 dose cohort 49 Rodger Weismann 49 randomized controlled multicenter 49 ENDEAVOR IV clinical 49 Spiegelmer ® 49 TransVax tm 49 Laurence Klotz 49 guanfacine extended release 49 torezolid phosphate 49 Wayne Katon 49 dose escalation Phase 49 Cheryl Bushnell 49 EDEMA4 49 PREGNANT PROCHIEVE Extending GestatioN 49 Lucie Bruijn 49 Biopharmaceuticals AG 49 European Sepsis Trial 49 randomized controlled Phase 49 Jorge Cortes MD 49 preclinical toxicology 49 Addex Pharmaceuticals Ltd. 48 Chief Executive Jouko Karvinen 48 inhaled AAT 48 Charles L. Dimmler 48 TRO# 48 PRESEPT study 48 ARCALYST ® 48 HIGHYAG 48 Bergenstal 48 NO# [002] 48 Ozarelix 48 dopamine partial agonist 48 trastuzumab DM1 48 Phase 1b clinical 48 hyperphenylalaninemia HPA due 48 Dr. Roehrborn 48 PDE4 inhibitor 48 EXPLORE Xa 48 PDP MLR 48 isavuconazole 48 overt nephropathy 48 dopaminergic therapy 48 Flutiform ™ 48 hour bronchodilation 48 Ronald Ede 48 Rando Allikmets 48 VALOR trial 48 PEARL SC 48 Ostabolin C TM 48 romidepsin novel 48 Omenn 48 hGH CTP Phase 48 candidate brentuximab vedotin 48 VaD 48 Richard Nesto 48 Fund TSX AIF.UN 48 Pat Mackin 48 Gheorghiade 48 COSTAR II 48 AIMM trial 48 ALN VSP Phase 48 Oncotype DX colon cancer 48 confirmatory pivotal 48 immune modulating 48 CAMBRIDGE Mass. Biogen Idec 48 Doug Godshall 48 Trastuzumab DM1 48 oral taxane 48 Archexin 48 selectin antagonist 48 adecatumumab MT# 48 Minister Eka Sguladze 48 exploratory Phase IIa 48 Thorough QT Study 48 Vasogen Celacade TM 48 Phase 1b 48 GLP toxicology studies 48 SIMPADICO trial 48 Anthony DiTonno President 48 VANTAS ® 48 Dr. Mace Rothenberg 48 Adjunct Clinical 48 cathepsin K inhibitor 48 Andre Michel Ballester 48 EGS# 48 omacetaxine mepesuccinate 48 Phase Ia 48 postoperative pulmonary 48 Sandra Horning 48 Alex Lukianov Chairman 48 Phase III HEAT 48 Mtsare Khevi Field 48 Iruela Arispe 48 agency carcinogen classifications 48 IMC #B 48 Zivadinov 48 includes Prototype Demonstration 48 Evamist TM 48 registrational trial 48 dermatologic diseases 48 Eugene Braunwald MD 48 Kurzrock 48 Prodarsan ® 48 Cloretazine R VNP#M 48 Matthew Meyerson 48 Camillo Ricordi MD 48 Amir Lerman 48 Bipolar Disorders 48 SCENESSE ® 48 vivo glucose 48 Jon Faiz Kayyem 48 Phase III 48 generation proteasome inhibitor 48 non cirrhotic portal 47 Novartis Molecular Diagnostics 47 Karl Swedberg 47 registrational 47 Frank Calderoni 47 Elmar Schnee 47 inhaled formulation 47 oral treprostinil 47 Stephen Huhn 47 Phase 2a clinical trials 47 initiate Phase IIa 47 Phase IIa clinical trials 47 dose escalation phase 47 CATIE AD 47 Martha L. Daviglus 47 Alan Menter 47 Braunwald 47 Initiate Phase 47 tasisulam 47 Bruce Psaty 47 Bart De Smet 47 HuMax EGFr 47 delta opioid receptor 47 CAPACITY trials 47 modified REGENESIS Phase IIb 47 Phase IIb trial 47 5 HT6 receptor 47 Phase III multicenter 47 LUMINATE 47 Dabelea 47 quarter# 47 NASDAQ ANIK 47 Phase Ib clinical trials 47 Thase 47 GPS IIIA satellite 47 MKC# MT 47 antituberculosis 47 EXJADE 47 QNEXA ® 47 Phyllis Zee 47 EDARBI 47 Debasish Roychowdhury 47 ARDIS 47 GLP1 agonist 47 Catherine DeAngelis 47 Nedim Cen 47 BLOOM Behavioral modification 47 Fast Tracked Phase 47 DDP# 47 Philip Poi 47 multicenter phase 47 controlled multicenter Phase 47 immune modulatory 47 Phase 2b clinical trials 47 IIa clinical 47 pseudobulbar affect PBA 47 James C. Thyen 47 TKM Ebola 47 Andrew Leuchter 47 peripheral arterial occlusive disease 47 Telatinib 47 oral RELISTOR 47 Herm Rosenman 47 Phase #b/#a trial 47 XpandR 47 titration phase 47 heart wrenching Hrkac 47 Acetavance TM intravenous acetaminophen 47 Dr. Massimo Cristofanilli 47 generation PNP inhibitor 47 LibiGel testosterone gel 47 Monica Mita 47 Phase IIa 47 Michael Gnant 47 BioMarin Genzyme LLC 47 Phase III placebo controlled 47 canagliflozin 47 placebo controlled Phase III 47 Nickolas Papadopoulos 47 receptor tyrosine kinase inhibitor 47 CONSERV 47 noninvasive outpatient 47 generation rotary VAD 47 Jean Luc Urbain 47 Tasigna prolongs 47 Known hypersensitivity 47 Dr. Francesco Bellini 47 androgen depletion therapy 47 Maximum Tolerated Dose 47 Kristine Yaffe MD 47 ATACAND 47 IMPACT DCM clinical 46 Les Iversen 46 Gilles Delfassy 46 phase IIb III 46 Luveris 46 Carlo Alberto Defanti 46 Phase IIa trials 46 Developmental Neuroscience 46 Dana Kammersgard president 46 Phase 2b 46 Urocidin 46 Doreen Toben Verizon 46 Therapeutics TCT scientific 46 Charles Smulders vice 46 JunJing II 46 gluteal injection 46 dose escalation trial 46 sacral neuromodulation 46 Jean Pierre Routy 46 Zerenex 46 Inc. NYSE WNI 46 Dr. Kantarjian 46 Diamyd R 46 myelofibrosis polycythemia vera 46 Loramyc TM 46 Certolizumab pegol 46 Guoping Feng 46 Phase IIIb 46 Phase III clinical trials 46 Professor Ludwig Kappos 46 Alfred Sandrock MD Ph.D. 46 Koffrie 46 Perceiva 46 Ruschitzka 46 Benjamin Rashleger 46 J. Ursano 46 Dr. Cassian Yee 46 Bruce Gellin 46 Libby adit 46 allogeneic HSCT 46 Nutritional Metabolism 46 Rachel Manber 46 RESTORE CLI trial 46 avanafil PDE5 inhibitor 46 randomized Phase III 46 psoriatic arthritis PsA 46 IMGN# 46 Potiga 46 pivotal Phase III 46 polycythemia vera essential thrombocythemia 46 OLpur TM H2H 46 Raymond V. Gilmartin 46 multicenter randomized placebo controlled 46 confirmatory Phase 46 FORTIS M trial 46 Eliezer Zomer Ph.D. 46 PYY #-# 46 Joseph S. Cantie 46 hyperprolactinemia 46 Michael Kaplitt 46 Dr. Julio Montaner 46 APF# Phase 46 ChronVac C ® 46 PREOS R 46 anticancer compound 46 IIa clinical trials 46 Portenoy 46 Jeffrey Apfelbaum 46 Dr. Hagop Kantarjian 46 generation purine nucleoside 46 Solorel 46 Diamyd r vaccine 46 PMA submission 46 Xcellerated T Cells 46 selective modulator 46 Testosterone MDTS ® 46 investigational biologic 46 financialresults 46 Rheos System 46 InfaCare 46 cardio metabolic diseases 46 hepatocellular carcinoma liver 46 Kaplitt 46 hepatitis B vaccine Heplisav 46 registrational Phase 46 InterStim 46 MARVEL Trial 46 Orosi Mill project 46 Phase IIA 46 Dennis Selkoe 46 INVEGA ® SUSTENNA ® 46 cutaneous lupus 46 MD FACS FAAP 46 basilar migraine 45 OLYMPIA registry 45 NUCRYST Pharmaceuticals 45 Dextofisopam Phase 2b 45 IND Investigational New 45 Peter R. Kowey 45 thefourth quarter 45 MD PhD DSc 45 DSMB 45 Kadan Lottick 45 Peter Goadsby 45 PrevOnco ™ 45 anginal pain 45 retaspimycin 45 rheumatoid arthritis osteoarthritis ankylosing 45 interventional neuroradiology 45 PGP Acquisition 45 AAPOS 45 Diamyd ® 45 Selwyn Joffe chairman 45 Jonathan Berek 45 dose escalation clinical 45 midstage studies 45 Caeté Project 45 EnteroMedics proprietary neuroblocking technology 45 constipation OIC 45 Evoltra R 45 CDAD Clostridium difficile 45 IIb clinical trial 45 IMiDs ® compound 45 Eltek commented 45 Kotloff 45 Phase 2a proof 45 Surgical Implant Division 45 fiscal# 45 REGEN trial 45 Phase IIb 45 Neurodex TM 45 AthenaHealth 45 Phase 1b dose escalation 45 oglemilast 45 Severe hypersensitivity reactions 45 Idenix anticipates 45 Digestive Diseases Week 45 Pulmonary Arterial Hypertension PAH 45 chromium supplementation 45 Dr. Tej Maini 45 ColorectAlert TM 45 Wong Rieger 45 Helen Mayberg 45 Hitoshi Oshitani 45 erythema nodosum 45 Yuval Weiss 45 Egrifta 45 LymphoStat B Phase 45 Breast Oncology 45 OPT CHF 45 Dr. Rebecka Meyers 45 Kenneth Kornman 45 TUI Mein Schiff 45 LAE reserves 45 Trebek escaped 45 Syncria albiglutide 45 Dave Tacelli chief 45 chronic thromboembolic pulmonary 45 Inc. NASDAQ DWRI 45 Thorough QT TQT 45 Ken Shifrin 45 Roxana Mehran MD 45 antiseizure 45 retinal degenerative disease 45 Noninterest Expense Noninterest expense 45 OLpur TM MD 45 Odaniell 45 Weihong Song 45 dose escalation 45 gastrointestinal metabolic 45 Trevor Mundel MD 45 CFO Hal Mechler 45 recurrent glioblastoma multiforme 45 prodromal phase 45 Andrea Natale 45 ICESS 45 Board INTZ Intrusion 45 Heap Leach Project 45 Chronic pancreatitis 45 imetelstat GRN#L 45 human microdosing 45 R#/MEM 44 aldosterone antagonists 44 abdominal aortic aneurysms AAA 44 immunomodulatory agents 44 Phase III TRIST 44 Beike Holdings 44 vinca alkaloid 44 Albuferon Phase 44 de novo kidney transplant 44 DiamondFlo TM 44 Phase III trials 44 phase III SIMPADICO 44 Dr. Anthony Caputy 44 Jeffrey Kindler Pfizer 44 modestly dilutive 44 pharmacologic therapies 44 Transgene therapeutic 44 author Karin Michels 44 Kronos Worldwide KRO 44 Nanette Wenger 44 UVIDEM 44 Michael Capellas MCI 44 aMCI precursor 44 Marie Paule Kieny WHO 44 MVA MUC1 IL2 44 causative pathogen 44 Clent Richardson 44 COSIRA trial 44 generation NNRTI 44 Tarvacin Anti Cancer 44 blinded randomized placebo controlled 44 pentostatin 44 INVEGA ® 44 MARRIOTT REVENUES totaled 44 DEEP AF 44 Rajiv Pancholy 44 Progressive Multifocal Leukoencephalopathy 44 Stroucken 44 Dementia Related Psychosis 44 MDS AML 44 Arsenic trioxide 44 initiate Phase Ib 44 neurocognitive deficits 44 Bruce Weitzberg CEO 44 Testosterone MDTS R 44 REVIVE Diabetes 44 Conner Entrust 44 dosing cohort 44 Dr. Zelenetz 44 Talotrexin 44 Levacor 44 LATUDA 44 DAC HYP 44 Romiplostim 44 Dick Komiyama 44 Franco Cavalli 44 National Surgical Adjuvant 44 Dr. KM Cherian 44 Dr. Madhukar Trivedi 44 oral PTH 44 Fergus Macbeth 44 PIX# trial 44 Holli Nichols 44 SCAI Annual 44 Talabostat 44 Leo Verhagen 44 Orosi Mill Project 44 multicentre prospective 44 symptom flare ups 44 prospective multicenter randomized 44 aromatase inhibitor therapy 44 Donna Ambrosino 44 alter anticoagulant 44 Functional Neurosurgery 44 ritonavir boosted danoprevir 44 bapineuzumab AAB 44 underwent prostate biopsy 44 oral opioid modulator 44 Elizabeth Nabel 44 Simon Lovestone 44 Joseph Zabramski 44 Frontal lobe 44 placebo controlled Phase 44 myocardial ischaemia 44 FQ = fiscal 44 Phase 1a 44 Hovnanian trims 44 Luveniq 44 Dr. Francesco Rubino 44 main CA tenance 44 Oparil 44 Eric Kossoff 44 Lance Kriegsfeld 44 Rotigotine 44 post herpetic 44 Kevin Grumbach 44 Peter Ubel 44 Michael Kourey Polycom 44 Zao Zhuang joint venture 44 NxStage anticipates 44 hemodynamically stable 44 GSM1x 44 Barry Katzen 44 induce orthostatic hypotension 43 follicular non 43 Vincent Cogliano 43 clinically heterogeneous 43 Dr. Zayd Eldadah 43 Sonia Caprio 43 Pending regulatory approvals 43 Rituxan infusion 43 Corp. Nasdaq ESMC 43 Gracia Martore 43 cardiometabolic diseases 43 FDA Oncologic Drugs 43 Phase III randomized controlled 43 Andrew Simor 43 systemic mastocytosis 43 William Maisel cardiologist 43 acute hepatic 43 Vinyls segment 43 MPP MPH 43 CAIRO Orascom 43 IIa trials 43 Engage Analytics 43 Lymphocytic 43 ENGAGE AF TIMI 43 Biological Therapy 43 Herbert Kleber 43 CombAT 43 Dr. Steven DeKosky 43 Gary Giovino 43 therapeutically inactive prodrug 43 Rachel Brem 43 Dr. Felix Umansky 43 Mofenson 43 Qnexa TM 43 Paul Biddinger associate 43 William Thies 43 TransMID 43 intra abdominal abscess 43 developing Bicifadine serotonin 43 pivotal Phase 43 A. Meeusen 43 William L. Trubeck 43 thorough QT 43 Judith Hochman 43 Erythropoietic therapies may 43 generation rPA anthrax 43 Sheldon Tobe 43 recurrent ischemia 43 Luigi Fontana 43 Hypotension 43 Vulnerable Plaque 43 airflow limitation 43 herpes zoster shingles 43 Francine Kaufman MD 43 Dr. Ira Goldknopf 43 Hamid R. Moghadam 43 Phase Ib IIa clinical 43 Psychiatric Assn 43 Juergen Dormann 43 RenalGuard System TM 43 Prodarsan 43 Iain Frame 43 Phase IIa proof 43 upon rechallenge 43 Daisy Acosta 43 Initiated Phase 43 Charles Smulders Gartner 43 receiving chemoradiation therapy 43 Cancer Immunobiology Center 43 QSGI commented 43 ischemic cardiac 43 Jean Neveu 43 MI Developments announces 43 Jerome Caille 43 Gastrointestinal Oncology 43 Dr. Coppari 43 BLA submission 43 cardiac revascularization 43 Nora D. Volkow 43 Piero Anversa 43 IND enabling 43 Boden Albala 43 unrefreshing sleep 43 Heterozygous Familial Hypercholesterolemia 43 TSX FTG 43 malignant pancreatic 43 National Instruments NATI 43 AZX# Phase 43 Dr. William Wijns 43 iSBTc 43 StemEx 43 resultsof 43 clinical trials Archexin 43 Pulse oximetry 43 Inc. Nasdaq IESC 43 Nasdaq NIHD 43 Phase IIb kidney transplant 43 placebo controlled randomized 43 Masaru Kato Sony 43 prolongs survival 43 CEO Wolfgang Ziebart 43 Valeri Liukin stood 43 ToleroMune R 43 double blinded placebo 42 Achillion anticipates 42 Adrian Di Bisceglie 42 Wireline adjusted EBITDA 42 natriuresis 42 MIRCERA 42 Dr. Alan Peaceman 42 ICD implantation 42 Imvamune R 42 Paul Twomey ICANN 42 Dr. Atul Mehta 42 Phase 2a preventative 42 Brugada syndrome 42 Medscape Oncology 42 Sepracor anticipates 42 VICTOR E1 42 Federal Mogul Alapont 42 Angela Genge 42 Dr. Donald Glower 42 fledgling Arpanet network 42 Rampura Agucha mine 42 NTDDS platform 42 fecal spores 42 Steven Panagos 42 perinatal morbidity 42 registrational trials 42 Airvana anticipates 42 atrial arrhythmias 42 Gangwisch 42 Impaired Glucose Tolerance 42 beta blocker therapy 42 marketed workover rigs 42 RiVax 42 S. aureus sepsis